TIL 66.1 (+2.02%)
US45783C1018BiotechnologyBiotechnology

Instil Bio (TIL) Stock Highlights

66.1 | +2.02%
2024-09-19 04:16:09
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using our Co-Stimulatory Antigen Receptor, or CoStAR, platform. The companys lead product candidate, ITIL-168, is an autologous TIL therapy that it is initially developing for the treatment of PD-1-inhibitor relapsed or refractory advanced melanoma.

Statistics

Range Today
60.01 73.69
Volume Today 540.1K
Range 1 Year
6.08 92
Volume 1 Year 17.43M
Range 3 Year
6.08 473.6
Volume 3 Year 33.49M
Range 10 Year
6.08 589.8
Volume 10 Year 35.6M

Highlights

Market Capitalization 549.71M (small)
Floating Shares 3.01M
Current Price 66.1
Price To Earnings -2.72
Price To Book 2.82
Earnings Per Share -18.39
Payout Ratio 0%

Performance

Latest +2.02%
1 Month +541.75%
3 Months +576.56%
6 Months +437.4%
1 Year +637.72%
3 Years -82.68%
5 Years -87.76%
10 Years -87.76%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.